Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Biomed 777; SH 489; ZK 95639

Latest Information Update: 11 Oct 2007

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Intarcia Therapeutics
  • Class Antineoplastics
  • Mechanism of Action Aromatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Benign prostatic hyperplasia; Breast cancer

Most Recent Events

  • 31 Jan 2005 Intarcia Therapeutics has completed enrolment in the first phase III trial (Biomed 777-CLP-29 study) for Breast cancer in the US, Canada, Russia and Ukraine
  • 31 Dec 2004 Intarcia Therapeutics has initiated enrolment in the CAT study for Breast cancer in the US and Europe
  • 02 Dec 2004 This compound is still in active development for Breast cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top